temozolomide has been researched along with bmn 673 in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 5 (55.56) | 2.80 |
Authors | Studies |
---|---|
Feng, Y; Gao, Y; Gong, W; Guo, Y; Huo, CX; Jiang, B; Kuang, X; Liu, X; Liu, Y; Luo, L; Lv, L; Peng, H; Qi, R; Qin, Z; Qiu, M; Ren, B; Su, D; Sun, X; Tang, T; Wang, F; Wang, H; Wang, L; Wang, X; Wang, Z; Wei, M; Wu, Y; Xu, D; Xu, H; Yan, H; Yu, F; Zhao, Y; Zhou, C; Zhu, Y | 1 |
Doroshow, JH; Huang, SY; Ji, J; Morris, J; Murai, J; Pommier, Y; Renaud, A; Takeda, S; Teicher, B; Zhang, Y | 1 |
Bahrami, A; Benavente, C; Bradley, C; Calabrese, C; Caufield, W; Dyer, MA; Freeman, BB; Gordon, B; Goshorn, R; Griffiths, LM; Hatfield, MJ; Karlström, Å; Loh, A; Miller, GM; Pappo, A; Potter, PM; Sablauer, A; Shelat, AA; Shirinifard, A; Snyder, SE; Stewart, E; Thiagarajan, S; Tsurkan, L; Twarog, NR; Wu, J | 1 |
Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, RB; Lyalin, D; Maris, JM; Reynolds, CP; Smith, MA | 1 |
de Stanchina, E; Desmeules, P; Gardner, EE; Lok, BH; Ni, A; Poirier, JT; Powell, SN; Rekhtman, N; Riaz, N; Rudin, CM; Schneeberger, VE; Teicher, BA | 1 |
Bahrami, A; Bishop, MW; Brennan, RC; Campagne, O; Clay, MR; Federico, SM; Furman, WL; Gartrell, J; Godwin, K; Hawkins, D; Helmig, S; Kaste, SC; McCarville, MB; Pappo, AS; Sahr, N; Santana, VM; Shelat, A; Stewart, CF; Stewart, E; Sykes, A | 1 |
DuRoss, AN; Landry, MR; Neufeld, MJ; Sun, C; Thomas, CR | 1 |
Hirota, K; Ibrahim, MA; Masutani, M; Ooka, M; Sasanuma, H; Shimizu, N; Takeda, S; Tsuda, M; Yamada, K; Yamada, S | 1 |
Brennan, M; Chmielowski, B; Finn, RS; Glaspy, JA; Goldman, J; Hecht, JR; Konecny, GE; Martinez, D; McCann, KE; O'Brien, N; Price, MM; Singh, AS; Slamon, DJ; Von Euw, E; Wainberg, ZA; Yonemoto, L | 1 |
2 trial(s) available for temozolomide and bmn 673
Article | Year |
---|---|
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Humans; Irinotecan; Male; Neoplasms; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Young Adult | 2020 |
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Irinotecan; Neoplasms; Temozolomide | 2023 |
7 other study(ies) available for temozolomide and bmn 673
Article | Year |
---|---|
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Topics: Animals; Binding Sites; Carbazoles; Cell Proliferation; Dogs; Female; Fluorenes; Half-Life; Humans; Indoles; Isoenzymes; Mice; Microsomes; Molecular Docking Simulation; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2020 |
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Topics: Adenosine Triphosphate; Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorescence Polarization; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Methyl Methanesulfonate; Molecular Structure; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Stereoisomerism; Temozolomide | 2014 |
Targeting the DNA repair pathway in Ewing sarcoma.
Topics: Animals; Benzimidazoles; Camptothecin; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Enzyme Inhibitors; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sarcoma, Ewing; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Humans; Immunoblotting; Mice; Mice, SCID; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genomics; Humans; Indoles; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Small Cell Lung Carcinoma; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cancer.
Topics: Animals; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Hafnium; Humans; Mice; Nanoparticles; P-Selectin; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Polysaccharides; Radiation Tolerance; Temozolomide | 2021 |
XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA.
Topics: Adenosine Diphosphate Ribose; Alkylating Agents; DNA; DNA Damage; DNA Repair; Methyl Methanesulfonate; Phthalazines; Piperazines; Poisons; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2022 |